JPRN-jRCT2080222658已完成1 期
A Phase 1b Study of LY2157299 in Combination with Sorafenib in Patients with Unresectable Hepatocellular Carcinoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Have histological evidence of a diagnosis of HCC (except HCC with fibrolamellar or mixed histology) not amenable to curative surgery.
- •-Have Child-Pugh Class A.
- •-Have the presence of measurable or evaluable lesion as defined by the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. A measurable or evaluable lesion showing demonstrable progression after locoregional therapy could be also included.
- •-Have not received sorafenib prior to enrollment.
- •-Have resolution to Grade less than or equal 1 by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 of all clinically significant toxic effects of prior locoregional therapy, surgery, chemoembolization, systemic chemotherapy.
- •-Have a performance status of less than or equal 1 on the Eastern Cooperative Oncology Group (ECOG) scale.
排除标准
- •-Are currently enrolled, or discontinued within 28 days prior to enrollment from, a clinical trial involving an investigational product or nonapproved use of a drug or device (other than the investigational product used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
- •-Have undergone major surgery within 28 days prior to enrollment.
- •-Have undergone hepatic locoregional therapy (including radiation, surgery, hepatic arterial embolization, chemoembolization, radiofrequency ablation, cryoablation, percutaneous ethanol injection, or percutaneous microwave coagulation therapy) within 28 days prior to enrollment.
- •-Have moderate or severe cardiac disease.
- •.Myocardial infarction within 6 months prior to enrollment, unstable angina pectoris, NewYork Heart Association (NYHA) Class III/IV congestive heart failure, or uncontrolled hypertension.
- •.Documented major electrocardiogram (ECG) abnormalities at the investigator's discretion within 28 days prior to enrollment.
- •.Major abnormalities documented by echocardiography with Doppler at investigator's direction within 28 days prior to enrollment.
- •.Have persistently elevated brain natriuretic peptide (BNP) or elevated troponin I within 14 days prior to enrollment.
- •.Predisposing conditions that are consistent with development of aneurysms of the ascending aorta or aortic stress.
- •.Have a history of cardiac or aortic surgery.
- •-Have undergone liver transplant.
- •-Are pregnant or breastfeeding.
研究者
相似试验
未知
1 期
A Phase 1b Study of LY2157299 in Combination With Gemcitabine in Patients With Advanced or Metastatic Unresectable Pancreatic Cancer (H9H-JE-JBAO)Pancreatic NeoplasmsJPRN-jRCT2080222513Eli Lilly Japan K.K.
进行中（未招募）
1 期
A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Brain CancerGlioblastoma Multiforme (GBM)MedDRA version: 14.1Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022160-13-DEEli Lilly and Company62
未知
1 期
A Phase 1 Study of LY2127399 in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed or Refractory Multiple MyelomaMultiple MyelomaJPRN-jRCT2080221743Eli Lilly Japan K.K.
进行中（未招募）
1 期
Randomized Phase 2 Study of LY2157299 in Patients with Hepatocellular Carcinoma who Have Had DiseaseProgression on Sorafenib or Are Not Eligible to Receive Sorafenib - NDMedDRA version: 13.1Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Hepatocellular CarcinomaEUCTR2010-022338-10-ITEli Lilly and Company204
进行中（未招募）
不适用
Randomized Phase 2 Study of LY2157299 in Patients with Hepatocellular Carcinoma who Have Had Disease Progression on Sorafenib or Are Not Eligible to Receive SorafenibEstudio en fase 2 aleatorizado de LY2157299 en pacientes con carcinoma hepatocelular que han presentado progresión de la enfermedad con sorafenib o no son aptos para recibir sorafenibcarcinoma hepatocelularMedDRA version: 12.1Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentEUCTR2010-022338-10-ESilly S.A.183